[EN] PHARMACEUTICAL COMPOSITION CONTAINING 1,2-DITHIOLTHIONE DERIVATIVE FOR PREVENTING OR TREATING DISEASE CAUSED BY OVEREXPRESSION OF LXR-ALPHA<br/>[FR] COMPOSITION PHARMACEUTIQUE CONTENANT UN DÉRIVÉ DE 1,2-DITHIOLTHIONE POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE CAUSÉE PAR LA SUREXPRESSION DE LXR-ALPHA
申请人:SNU R&DB FOUNDATION
公开号:WO2010016681A2
公开(公告)日:2010-02-11
Provided is a pharmaceutical composition that contains a 1,2-dithiolthionederivative, and is effective to prevent and treat a disease caused by overactivity of a liver X receptor α (LXR α ) or a sterol response element binding protein (SREBP-1). Specifically, the pharmaceutical composition includes 1,2-dithiolthione derivatives such as 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione, 3-methyl-1,2-dithiol-3-thione, or 5-(6-methoxypyrazinyl)-4-methyl-1,2-dithiol-3-thione. The pharmaceutical composition is effective for preventing and treating hypertension caused by renin, aldosteronism, adrenoleukodystrophy, glomerulosclerosis, proteinuria, nephropathy, liver steatosis, hypertriglyceridemia or hyperreninemia.
Abrogation of Hyperosmotic Impairment of Insulin Signaling by a Novel Class of 1,2-Dithiole-3-thiones through the Inhibition of S6K1 Activation
作者:Eun Ju Bae、Yoon Mee Yang、Sang Geon Kim
DOI:10.1124/mol.107.044347
日期:2008.5
factor-alpha-induced hepatic insulin resistance via AMP-activated protein kinase-dependent p70S6 kinase (S6K) 1 inhibitory pathway. This study investigated whether oltipraz and a novel class of 1,2-dithiole-3-thiones were capable of preventing insulin resistance induced by hyperosmotic stress, thereby enhancing insulin-dependent signals, and, if so, whether the restoration of insulin signal was mediated